Seeking Alpha


Send Message
View as an RSS Feed
View gschwaid's Comments BY TICKER:
Latest  |  Highest rated
  • Vapor Corp - It's Smoking [View article]
    As a doctor practicing Public Health & Preventive Medicine, I'm torn.

    The medical industry is gearing up for a war on Electronic Nicotine Delivery Systems, ENDS. Nicotine products have found their way back into mainstream advertising, after successfully advocation to ban many forms of its marketing. Most professional colleges (American Academy of Pediatrics, etc.) do not support ENDS. Data on efficacy of tobacco cessation rates are mixed. One thing that is for sure is that children are using ENDS and becoming addicted to nicotine. Many have taken the jump to tobacco cigarettes. As mentioned in the article, the FDA and other governmental entities have already begun to take notice.

    On the other hand, this industry is clearly growing and there is a lot of money to be made.
    Jan 30 01:54 PM | 2 Likes Like |Link to Comment
  • How To Play Organovo Holdings [View article]
    The title of this article was very misleading. I was hoping to read your viewpoint on the stock's volatility.
    Dec 22 02:02 PM | 6 Likes Like |Link to Comment
  • OxySure Continues Progress Towards Profitability [View article]
    Thank you for the article. I've been keeping my eye on this company for quite a while now. I plan on jumping on board as soon as they solve their immediate need for capital.
    Nov 18 03:54 PM | Likes Like |Link to Comment
  • This Antibiotic Play May Be The Trius Of 2014 [View article]
    Interesting article. As an Urgent Care Physician, I'm always looking for new antibiotics to try. I wonder why they chose Moxifloxacin as the control. It is not in the same class and isn't very widely used (at least in my area of the country).
    Thanks to your article, I will look a little deeper into Cempra.
    Nov 15 12:41 PM | 4 Likes Like |Link to Comment
  • Arena Revises SEC Filing On APD811 [View article]
    Don't forget that PAH predisposes you to have A Fib.
    Aug 29 11:19 AM | 4 Likes Like |Link to Comment
  • Arena Revises SEC Filing On APD811 [View article]
    Don't be fooled just because the name of the disease is Pulmonary Arterial Hypertension. It has the ability to be 100% a cardiovascular disease. I'm in ARNA the for Belviq, and I have yet to look at which of the five types of PAH this medication is looking to treat.
    Aug 29 11:18 AM | 3 Likes Like |Link to Comment
  • Arena Revises SEC Filing On APD811 [View article]
    The three year survival rate after diagnosis of PAH hovers somewhere around 65%. Transient Atrial Fibrillation's prognosis is much higher. Although the risk-reward benefit is not as great as it was yesterday, I would still place my patients on an effective PAH medication. There are many effective medications for those with A Fib.
    Aug 29 11:13 AM | 6 Likes Like |Link to Comment
  • The Disruptive Potential Of Inovio's SynCon DNA Vaccines [View article]
    I don't follow Chrontech very closely, but I do remember hearing that a likely culprit of their failed HCV trial was that they used a smaller dose of vaccination. I will reserve my opinion of the company until I see the results with a larger dose.
    Aug 23 01:36 AM | 3 Likes Like |Link to Comment
  • Inovio Overextended At $2? [View article]
    In conclusion, the author is evaluating the market cap of a biotech company without evaluating the current technology.
    Aug 6 09:49 PM | 7 Likes Like |Link to Comment
  • MannKind: Facts And Fundamentals Over Fiction And Fear [View article]
    I was responding to rthargrave's comment, where he asked for someone to show him a startup company without any debt.
    Aug 6 01:18 PM | Likes Like |Link to Comment
  • MannKind: Facts And Fundamentals Over Fiction And Fear [View article]
    INO has no debt.
    Aug 6 12:44 AM | Likes Like |Link to Comment
  • Iroko Pharmaceuticals: An Emerging Threat For Pfizer's 'Celebrex', And A Positive Risk Reward Ratio [View article]
    They're entering a saturated market without enough to distance themselves from the rest.
    Jul 27 03:46 PM | Likes Like |Link to Comment
  • Organovo: Red Hot But Set To Drop [View article]
    Although I agree that ONVO is currently overvalued, I disagree that their success would confine them to a niche market.
    If successful, they will revolutionize preclinical drug testing and create human tissues for implantation. These two applications fit the needs of many industries.
    Jul 24 02:30 PM | 5 Likes Like |Link to Comment
  • Inovio's Hepatitis C Data: What Does It Really Mean? [View article]
    From what I understand, ChronTech's HCV vaccine was not developed by Inovio. However, they are using Inovio's electroporation vaccine delivery technology. It is also important to note that Inovio is a partial owner of ChronTech.
    You're right in that the power of the study was too low to provide significant results. However, the it is encouraging that the vaccine delivery technique didn't yield adverse events.
    Inovio will release results from HIV (phase 2?) trials sometime in Q2. Possibly at a conference today.
    Apr 5 08:14 AM | 2 Likes Like |Link to Comment
  • Atossa Genetics: My Top Biotech Idea For 2013 [View article]
    Interesting article.

    I would've liked to see more biostatistics. With a test so specific, you're likely to find a lot of false-positives. This could lead to a lot of unnecessary biopsies and all the problems associated with it. Something like that would hold off the USPSTF from giving a Grade A or B recommendation.

    Also, do any of the competitors have any type of similar test?
    Mar 15 03:53 PM | Likes Like |Link to Comment